ABRF Survey Finds Half of Second-Gen Sequencer Owners Plan to Buy More

Of the survey's 69 participants, which primarily included core labs and academic institutes in the US, 37 currently have one or more sequencer from Roche/454, Illumina, or Applied Biosystems. Of those, 47 percent indicated that they plan to buy at least one more instrument in the next two years.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.